Skip to main content

Table 4 Univariable comparison of demographics, disease subtypes and serological profiles in patients with persistent normocomplementaemia and those with at least one episode of hypocomplementaemia

From: The association of low complement with disease activity in systemic sclerosis: a prospective cohort study

Characteristic Persistent normocomplementaemia (n = 865) At least one episode of hypocomplementaemia (n = 275)  
n (%) or mean ± SD or median (IQR) n (%) or mean ± SD or median (IQR) p Value
Age at diagnosis, years 46.4 ± 0.5 44.6 ± 0.8 0.071
Sex
 Male 113 (13.1 %) 35 (12.7 %) 0.89
 Female 752 (86.9 %) 240 (87.3 %) 0.89
Disease duration 11.3 ± 0.4 11.6 ± 0.7 0.71
  ≤ 2 years 117 (14.5 %) 46 (17.5 %) 0.24
  ≤ 5 years 268 (33.2 %) 88 (33.5 %) 0.94
Disease type
 Diffuse 238 (27.5 %) 72 (26.2 %) 0.67
 Limited 627 (72.5 %) 203 (73.8 %) 0.67
Overlap features presenta 186 (21.5 %) 81 (29.5 %) 0.007
 Rheumatoid arthritis 15 (1.7 %) 7 (2.6 %) 0.39
 Polymyositis 1 (0.1 %) 5 (1.8 %) 0.001
 Dermatomyositis 0 (0 %) 1 (0.4 %) 0.076
 Sjögren’s syndrome 14 (1.6 %) 7 (2.6 %) 0.32
 SLE 6 (0.7 %) 3 (1.1 %) 0.52
Serological profilea
 Anti-centromere ANA 391 (46.0 %) 126 (47.0 %) 0.084
 Anti-Scl-70 antibodies 134 (16.1 %) 33 (12.3 %) 0.13
 Anti-Jo-1 antibodies 4 (0.5 %) 1 (0.4 %) 0.82
 Anti-RNP antibodies 10 (1.2 %) 12 (4.5 %) 0.001
 Anti-Ro antibodies 43 (5.2 %) 29 (10.8 %) 0.001
 Anti-La antibodies 12 (1.5 %) 6 (2.2 %) 0.38
 Anti-Sm antibodies 2 (0.2 %) 4 (1.5 %) 0.016
 Anti-PM-Scl antibodies 10 (1.2 %) 5 (1.9 %) 0.43
 Anti-dsDNA antibodies 16 (2.5 %) 10 (4.9 %) 0.089
 Anti-RNAP antibodies 61 (13.6 %) 23 (12.6 %) 0.74
ANCA 95 (12.1 %) 39 (15.2 %) 0.20
  MPO specificity 14 (1.8 %) 3 (1.2 %) 0.50
  PR-3 specificity 14 (1.8 %) 8 (3.1 %) 0.20
 Rheumatoid factor 208 (26.1 %) 80 (31.3 %) 0.11
 Anti-phospholipid antibodies 192 (24.0 %) 80 (31.3 %) 0.02
  Cardiolipin IgM 115 (63.2 %) 50 (69.4 %) 0.351
  Cardiolipin IgG 78 (41.5 %) 27 (34.2 %) 0.26
 β2-glycoprotein 59 (32.8 %) 25 (33.3 %) 0.93
 Lupus anti-coagulant 15 (2.4 %) 11 (5.0 %) 0.056
  1. Abbreviations: ANA Anti-nuclear antibody, Anti-Scl-70 Anti-scleroderma-70 antibodies, Anti-RNP Anti-ribonucleoprotein antibodies, Anti-Sm Anti-Smith antibodies, Anti-PM-Scl Anti-polymyositis scleroderma antibodies, Anti-dsDNA Anti-double-stranded DNA antibodies, Anti-RNAP Anti-RNA polymerase antibodies, ANCA Anti-neutrophil cytoplasmic antibodies, MPO Myeloperoxidase, PR-3 Proteinase-3, Ig Immunoglobulin, SLE Systemic lupus erythematosus
  2. aEver from disease onset to most recent visit